Novo Nordisk (NVO.N) said its long-acting growth hormone injection, marketed in China as NuozeYou, received approval for three additional pediatric indications: growth retardation associated with Noonan syndrome in children aged 2.5 years and older; idiopathic short stature in children aged 2.5 years and older; and children born small for gestational age who remain short at age 2, for treatment in patients aged 2.5 years and older. The product was previously approved in China for pediatric growt

JP Morgan says US economic and corporate fundamentals remain intact but several near-term risks justify a more cautious stance. Key points: the Fed's September meeting again carries a risk of a rate hike, with CPI the key data; investor positioning shows no clear directional signal, implying elevated volatility over the next 3–4 weeks; post-Labor Day corporate issuance typically rises and could push credit spreads wider, weighing on equities; September is historically the weakest month for the S&P 500; momentum strategies have retraced sharply since June highs; and even very strong tech earnings may not be enough to sustain gains in AI, storage and semiconductor stocks.

RIA reported the Russian security service said Ukraine had planned to accuse Russia of carrying out a terror attack on the British embassy in Russia to draw the UK into direct armed conflict with Russia.